Please assess the completion status of the following clinical trial:

Trial Title: Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Giving written informed consent~* History of COPD (according to GOLD 2009) for at least 12 months prior to baseline Visit V0 associated with chronic productive cough for 3 months in each of the 2 years prior to baseline visit (with other causes of productive cough excluded)~* Age ≥ 40 years~* Forced expiratory volume after one second (FEV1)/forced vital capacity (FVC) ratio (post-bronchodilator) \< 70%~* FEV1 (post-bronchodilator) ≤ 50% of predicted~* At least two documented moderate or severe COPD exacerbations within one year prior to baseline visit~* Patients must be pre-treated with LABA and ICS for at least 12 months before baseline Visit V0. Up to 3 months before baseline Visit V0 free or fixed combinations of LABA and ICS are allowed, including changes in dose, active substances, and brands. In the last 3 months before baseline Visit V0 patients must be pre-treated with fixed combinations of LABA and ICS at a constant dose (maximum approved dosage strength of the combination).~* Former smoker (defined as smoking cessation at least one year ago) or current smoker both with a smoking history of at least 20 pack years~Main Exclusion Criteria:~* Exacerbations not resolved at first baseline visit~* Diagnosis of asthma and/or other relevant lung disease~* Known alpha-1-antitrypsin deficiency~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Roflumilast (Type: ACTIVE_COMPARATOR): concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
- Placebo (Type: PLACEBO_COMPARATOR): concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid

Based on this trial design, predict the completion outcome and termination type (if applicable).